Forte Biosciences, Inc.

NasdaqCM:FBRX 주식 보고서

시가총액: US$6.1m

Forte Biosciences 과거 수익 실적

과거 기준 확인 0/6

Forte Biosciences's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 19% annually.

주요 정보

-2.4%

수익 성장률

60.5%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률n/a
자기자본 수익률-210.8%
순이익n/a
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

수익 및 비용 분석

Forte Biosciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqCM:FBRX 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 240-361720
31 Mar 240-321221
31 Dec 230-311122
30 Sep 230-301021
30 Jun 230-24816
31 Mar 230-18910
31 Dec 220-1486
30 Sep 220-1284
30 Jun 220-1789
31 Mar 220-19811
31 Dec 210-22814
30 Sep 210-23716
30 Jun 210-20614
31 Mar 210-49512
31 Dec 200-46410
30 Sep 200-4338
30 Jun 200-3925
31 Mar 200-523
31 Dec 190-413

양질의 수익: FBRX is currently unprofitable.

이익 마진 증가: FBRX is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: FBRX is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

성장 가속화: Unable to compare FBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: FBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


자기자본 수익률

높은 ROE: FBRX has a negative Return on Equity (-210.82%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기